

I am participating in a special monitoring program which continues every month for 4 years after my last treatment.

I have been treated with LEMTRADA, a treatment for multiple sclerosis (MS), which affects the immune system,

Please show this card to all emergency and healthcare providers

Patient Alert Card

care may also be listed. below. Other doctors or healthcare protessionals involved in my My doctor prescribing LEM I RADA can be contacted at the number

of all medical records, including any treatments and/or test results, It any medical evaluations are undertaken, please provide copies

to the doctor(s) listed below.

ameN

:9meN in9lie4

MS Nurse Practitioner Neurologist

Patient Signature:



Autoimmune disorders such as:

basement membrane [anti-GBM] disease]

Doctors: See SmPC for more information.

Phone number

Serious Infections

> Problems of the thyroid gland (hypo/hyper thyroidism) > Kidney problems (nephropathies, including anti-glomerular)

LEMTRADA treatment may increase the risk of:

> A bleeding problem called Immune Thrombocytopenic Purpura (ITP)

Important side effects to watch for:

Call your doctor right away to report these symptoms. If you cannot reach your doctor seek immediate medical attention.

Autoimmune Conditions

Immune Thrombocytopenic Purpura - ITP

- > Small scattered spots on your skin that are red, pink or purple
- > Easy bruising
- Bleeding from a cut that is harder to stop
- Heavier, longer or more frequent menstrual periods than normal
- > Bleeding between your menstrual periods could also be a sign of ITP
- Bleeding from your gums or nose that is new or takes longer than usual to stop
- > Coughing up blood

Kidney problems or anti-GBM disease

- > Blood in the urine it may be red or tea-colored
- > Swelling in your legs or feet
- > Coughing up blood

Serious Infections

Also, tell your doctor right away if you have any of these signs of serious infection

- > Fever and/or chills
- > Swollen glands

Autoimmune conditions could occur long after you received a course of treatment with LEMTRADA. *It is very important that you continue to have your monthly tests (even if you are feeling well).*



Early detection and diagnosis may give you the best opportunity for improvement.



You must also continue to watch for signs and symptoms.



Do this for 4 years after your last course of treatment with LEMTRADA.



Call for reporting:

Healthcare professionals should report any adverse events suspected to be associated with the use of Lemtrada to Sanofi Malta Ltd., 3rd Floor, Avantech Building, St. Julian's Road, San Gwann SGN 2805. Tel: 21493022, fax 21493024 Alternatively any suspected ADRs and medication errors can be reported to the Medicines Authority. Report forms can be downloaded from www. medicines authority own/raid/optical and posted to Medicines Authority Postlicensing Directorate, 203, Level 3, Rue D'Argens, Caira G2R 1586, MALTA, or sent by email to positionesing-medicinesauthority@govmt

Lemtrada/Patient Card/EU Gen/Release date Nov 2013/EN